Endoscopic ultrasound (EUS) is an inevitable tool for locoregional staging of upper gastrointestinal, rectal, and pancreaticobiliary cancer. Transabdominal ultrasound (TUS) and computed tomography (CT) are the most important methods used for the detection of liver metastases and other distant metastases. However, despite its limited operation range, EUS and EUS-guided fine-needle biopsy (EUS-FNB) may add value to TUS and CT by detecting and proving 'occult' liver metastases and malignant ascites as well as nonregional lymph node metastases, adrenal metastases, and pleural carcinosis in approximately 5-20% of cases of pancreaticobiliary and upper gastrointestinal tract cancer. This article is part of an expert video encyclopedia.
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Background and Endoscopic Procedure
The ideal pretherapeutic cancer staging strategy provides reliable information on both locoregional and distant tumor spread. Guidelines recommend computed tomography (CT) and transabdominal ultrasound (TUS) as the most important methods for the detection of liver metastases and other distant metastases in pancreaticobiliary and upper gastrointestinal tract cancer (M-staging). [1] [2] [3] [4] The role of EUS in most guidelines is confined to locoregional staging. 1, 2, 4 Despite the high sensitivity of CT in detecting liver metastases and malignant ascites, due to limited spatial resolution of CT, liver and adrenal metastases o10 mm, small nonregional lymph nodes metastases (e.g., in the mediastinum) and very small amounts of ascites may escape detection in cancer patients. EUS has been shown to be very sensitive in detecting peritoneal fluid of only several milliliters and also liver metastases down to o5 mm, which are not detectable by CT. [5] [6] [7] However, EUS is not capable of visualizing the whole liver and all mediastinal, retroperitoneal, and visceral lymph node stations. Several studies have shown a high clinical impact of EUS and EUS-FNA in patients with esophageal, gastric, and pancreatic cancer, far beyond the classification of T-stage and N-stage. 8 In a recent study in patients with gastric cancer, EUS demonstrated suspected distant metastases in 35% of patients, and EUS-FNA proved distant spread ultimately in 16.2% of patients. 9 The most frequent locations of distant metastases in this study were mediastinal lymph nodes (65.6%), followed by nonregional abdominal lymph nodes (11.5%), liver metastases (9.8%), malignant ascites (6.6%), and adrenal or omental metastases (each 1.2%). As judged by the board of surgeons, EUS-FNA resulted in a change in the planned management in 14.5% of gastric cancer patients undergoing EUS, avoiding unnecessary surgery and indicating palliative treatment. 9 Very similar results have been reported for patients with gastric, esophageal, pancreatic, and pancreaticobiliary cancers: in approximately 5-20% of cases distal metastatic spread was proved by EUS and EUS-FNA, changing management plans in most cases. [10] [11] [12] [13] Patients with EUS-FNA-proven distant metastases of upper gastrointestinal and pancreaticobiliary cancer have a very poor prognosis. 6, 14 Therefore, in those patients, surgical exploration and further imaging should be avoided and palliative treatment should be initiated without delay. Beyond pretherapeutic M-staging, EUS and EUS-FNA may play a pivotal role in detecting and diagnosing recurrence or late distant spread of gastrointestinal cancer. [15] [16] [17] [18] [19] Owing to
This article is part of an expert video encyclopedia. Click here for the full • Endosonographic staging examinations of pancreaticobiliary, esophageal, and gastric cancer should not be restricted to locoregional (TN) staging; moreover, in every patient careful inspection of potential sites of metastatic spread, in particular mediastinal and other nonregional lymph node stations, (left) liver lobe, (left) adrenal gland, and pancreas, should be performed in addition. Ascites, pleural effusions, and peritoneal or pleural nodules should be watched out for.
• EUS-guided fine-needle biopsy (EUS-FNB) should be used to prove distant metastasis, peritoneal carcinosis, or pleural carcinosis in all cases in which other imaging methods have failed, or biopsy guidance by TUS or CT is regarded inappropriate or potentially unsafe.
• Penetration of the needle through obvious neoplastic tissue in the gastrointestinal wall must be avoided.
• According to the rules of TNM-classification, 25 ,26 a positive finding of EUS-FNB for distant metastases is classified pM1. Conversely, a negative cytopathological finding is classified cM0 unless, due to clinical and imaging findings, a high suspicion of metastasis is maintained (in this case the correct classification is cM1).
• In cases with suspected distant malignant spread, EUS-FNB should follow an inverse TNM-schedule. Particularly in a patient with a pancreatic mass which is suspicious for pancreatic cancer, a potential distant metastasis should be sampled first. If necessary, the same needle may be used subsequently for biopsy of a locoregional lymph node or of the pancreatic mass itself.
• EUS and EUS-FNB have a high yield for the detection and/ or proof of postoperative recurrence of pancreaticobiliary and gastrointestinal cancers, including colorectal cancer.
Immunohistochemistry is helpful for differentiation between recurrence of the previous cancer on the one hand and a second malignant tumor on the other.
Complications and Risk Factors
The complication rate of EUS-FNB is approximately 1-2%. 16 A systematic review demonstrated that EUS-FNB is exceptionally safe for mediastinal lymph nodes (complication rate: 0.38%), abdominal masses (complication rate: 0.26%), and adrenal gland biopsies (complication rate: 0%; only a few case reports of complications). EUS-FNB had an associated overall morbidity of 2.33% for liver lesions and 3.53% for ascites. 27 EUS-FNB of ascites carries a low but relevant risk of peritonitis. 28 Therefore, the authors propose peri-interventional antibiotic treatment. 27 
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